Vericel (VCEL) Expected to Post Quarterly Earnings on Thursday

Vericel (NASDAQ:VCEL) is anticipated to post its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect Vericel to announce earnings of ($0.04) per share and revenue of $72.6880 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, July 30, 2026 at 8:30 AM ET.

Vericel (NASDAQ:VCEL) last announced its earnings results on Thursday, May 7th. The biotechnology company reported ($0.12) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.03. The firm had revenue of $68.43 million for the quarter, compared to the consensus estimate of $63.68 million. Vericel had a return on equity of 6.41% and a net margin of 7.35%.The company’s revenue was up 30.1% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.23) EPS. On average, analysts expect Vericel to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Vericel Stock Up 3.1%

VCEL stock opened at $46.71 on Wednesday. The firm has a market cap of $2.39 billion, a PE ratio of 111.22 and a beta of 1.07. The business has a 50 day moving average of $41.26 and a 200-day moving average of $37.22. Vericel has a 12-month low of $28.95 and a 12-month high of $48.75.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on VCEL. Truist Financial lifted their price target on Vericel from $42.00 to $54.00 and gave the stock a “buy” rating in a report on Thursday, July 16th. HC Wainwright reiterated a “buy” rating and set a $70.00 target price on shares of Vericel in a research note on Tuesday. Wall Street Zen upgraded Vericel from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Finally, Weiss Ratings raised shares of Vericel from a “sell (d)” rating to a “sell (d+)” rating in a report on Tuesday, June 16th. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $57.00.

Insider Activity at Vericel

In other Vericel news, insider Jonathan Siegal sold 2,732 shares of the firm’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $44.90, for a total value of $122,666.80. Following the completion of the sale, the insider directly owned 886 shares of the company’s stock, valued at $39,781.40. This trade represents a 75.51% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Jonathan Mark Hopper sold 10,000 shares of the firm’s stock in a transaction on Friday, June 26th. The stock was sold at an average price of $45.00, for a total value of $450,000.00. Following the completion of the sale, the insider directly owned 75,753 shares of the company’s stock, valued at $3,408,885. This represents a 11.66% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 47,732 shares of company stock worth $2,084,167. Company insiders own 7.60% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in VCEL. First Trust Advisors LP purchased a new position in shares of Vericel in the fourth quarter worth about $224,000. Dynamic Technology Lab Private Ltd bought a new position in Vericel in the 4th quarter worth approximately $212,000. Tower Research Capital LLC TRC grew its stake in Vericel by 7,627.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,791 shares of the biotechnology company’s stock valued at $204,000 after buying an additional 4,729 shares in the last quarter. Connecticut Wealth Management LLC purchased a new position in Vericel in the 2nd quarter valued at approximately $201,000. Finally, iSAM Funds UK Ltd bought a new stake in Vericel during the 3rd quarter valued at $160,000.

Vericel Company Profile

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.